Upsher-Smith Receives Tentative NDA Approval for Vogelxo™ (testosterone) Gel CIII

MAPLE GROVE, Minn., Aug. 16, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., today announced that it has received tentative approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Vogelxo™ (testosterone) gel for topical use CIII.   

(Logo: http://photos.prnewswire.com/prnh/20130520/NY17281LOGO )

About Upsher-Smith 
Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company headquartered in Maple Grove, Minnesota that focuses on product growth and innovation for branded and generic pharmaceuticals.  Upsher-Smith has a particular focus on developing therapies to assist people suffering from central nervous system diseases and also markets products relating to cardiology, dermatology, and women's health.  For more information, visit www.upsher-smith.com.

SOURCE Upsher-Smith Laboratories, Inc.